Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-27T17:56:27.135Z Has data issue: false hasContentIssue false
  • English
  • Français

A decade of biological-psychiatric research in OCD (II): challenge-studies and neuroanatomical substrate

Published online by Cambridge University Press:  18 September 2015

A.S. De Leeuw ,
H.G.M. Westenberg  and
J.A. Den Boer
A.S. De Leeuw*
Affiliation:
afd. biologische psychiatrie, AZU
H.G.M. Westenberg
Affiliation:
afd. biologische psychiatrie, AZU
J.A. Den Boer
Affiliation:
afd. biologische psychiatrie, AZU
*
Academisch Ziekenhuis Utrecht, Afdeling Biologische Psychiatrie, Heidelberglaan 100, 3584 CX Utrecht
Get access Rights & Permissions [Opens in a new window]

Summary

In this second part of a review on OCD, challenge-tests are discussed and an overview is given of neuro-imaging studies. Subsequently some hypotheses concerning the pathogenesis of OCD are reviewed. The serotonin (5-HT) agonist metachloro-phenylpiperazine (mCPP) was found to lead to an increase in obsessive-compulsive symptoms. These studies revealed a dissociation between the behavioral and the neuroendocrine responses: OCD-patients showed a blunted hormonal respons compared to controls. Possibly different receptor subtypes are involved. One study is reported with a 5-HT1a agonist as a probe. This study lends no support to an involvement of the 5-HT1a receptor. Tests with noradrenergic probes showed unequivocal results.

Research on the neuroanatomic substrate of OCD is critically reviewed. PET-scan studies point to a possible role of the (orbito-)frontal cortex and the basal ganglia in OCD. Keywords: obsessive-compulsive disorder, OCD, challenge-test, serotonin (5-HT), mCPP, PET-scan.

Type
Research Article
Information
Acta Neuropsychiatrica , Volume 5 , Issue 1 , March 1993 , pp. 7 - 14
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1. De Leeuw, AS, Den Boer, JA, Westenberg, HGM. Een decennium biologisch psychiatrisch onderzoek bij obsessieve-compulsieve stoornis (I): inleiding en behandelingsonderzoeken. Acta Neurop-sychiat 1993; 5: 1–6.CrossRefGoogle Scholar
2.Kahn, RS, Wetzler, S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiat 1991; 30: 1139-66.CrossRefGoogle ScholarPubMed
3.Zohar, J, Mueller, EA, Insel, TR, Zohar-Kadouch, RC, Murphy, DL. Serotonergic responsivity in obsessive-compulsive disorder: comparisons of patients and healthy controls. Arch gen Psychiat 1987;44:946-51.CrossRefGoogle ScholarPubMed
4.Hollander, E, DeCaria, CM, Nitescu, A, Gully, R, Suckow, RF, Cooper, TB, Gorman, JM, Klein, DF, Liebowitz, MR. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch gen Psychiat 1992;49:21-8.CrossRefGoogle ScholarPubMed
5.Pigott, TA, Zohar, J, Hill, JL, Bernstein, SE, Grover, GN, Zohar-Kadouch, RC, Murphy, DL. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpi-perazine in patients with obsessive-compulsive disorder. Biol Psychiat 1991; 29: 418-26.CrossRefGoogle ScholarPubMed
6.Charney, DS, Goodman, WK, Price, LH, Woods, SW, Rasmussen, SA, Heninger, GR. Serotonin function in obsessive-compulsive disorder. Arch gen Psychiat 1988; 45: 177-85.CrossRefGoogle ScholarPubMed
7.Zohar, J, Insel, TR, Zohar-Kadouch, RL, Hill, JL, Murphy, DL. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch gen Psychiat 1988; 45: 167-72.CrossRefGoogle ScholarPubMed
8.Pigott, TA, Yoney, TH, L'Heureux, F. Serotonergic responsivity to m-CPP in OCD patients during clomipramine and fluoxetine treatment. Biol Psychiat 1990; 27: 41A–179A.Google Scholar
9.McBride, PA, DeMeo, MD, Sweeney, JA, Halper, J, Mann, JJ, Shear, MK. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. Biol Psychiat 1992; 31: 19–34.CrossRefGoogle ScholarPubMed
10.Lesch, KP, Höh, A, Disselkamp-Tietze, J, Wiesmann, M, Osterheider, M, Schulte, HM. 5-Hydroxytryptaminela receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch gen Psychiat 1991; 48: 540-7.CrossRefGoogle Scholar
11.Lesch, KP, Höh, A, Schulte, HM, Osterheider, M, Mueller, T. Long-term fluoxetine treatment decreases 5-HT1a receptor responsivity in obsessive-compulsive disorder. Psychopharmacol 1991b; 105: 415-20.CrossRefGoogle ScholarPubMed
12.Rasmussen, SA, Goodman, WK, Woods, SW, Heninger, GR, Charney, DS. Effects, of yohimbine in obsessive-compulsive disorder. Psychopharmacol 1987; 93: 303-13.CrossRefGoogle ScholarPubMed
13.Hollander, E, Decaria, C, Nitescu, A, Cooper, T, Stover, B, Gully, R, Klein, DF, Liebowitz, MR. Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to Clonidine and comparison to healthy controls. Psychiat Res 1991; 37: 161-77.CrossRefGoogle ScholarPubMed
14.Behar, D, Rapoport, JL, Berg, CJ, Denckla, MB, Mann, L, Cox, C, Fedio, P, Zahn, T, Wolfman, MG. Computerized tomography and neuropsychological test measures in adolescents with obsessive-compulsive disorder. Am J Psychiat 1984; 141: 363-9.Google ScholarPubMed
15.Luxenberg, JS, Swedo, SE, Flament, MF, Friedland, RP, Rapoport, J, Rapoport, SI. Neoroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. Am J Psychiat 1988; 145: 1089-93.Google ScholarPubMed
16.Baxter, LR, Phelps, ME, Mazziota, JC, Guze, BH, Schwartz, JM, Selin, CE. Local cerebral glucose metabolic rates inobsessive-compulsive disorder. A comparison with rates in unipolar depression and normal controls. Arch gen Psychiatry 1987; 44: 211-8.CrossRefGoogle ScholarPubMed
17.Baxter, LR, Schwartz, JM, Mazziotta, JC, Phelps, ME, Pähl, JJ, Guze, BH, Fairbanks, L. Cerebral glucose metabolic rates in non-depressed patients with obsessive-compulsive disorder. Am J Psychiat 1988; 45: 1560-3.Google Scholar
18.Swedo, SE, Shapiro, MB, Grady, CL, Cheslow, DL, Leonard, HL, Kumar, A, Friedland, R, Rapoport, SI, Rapoport, JL. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch gen Psychiat 1989; 46: 518-23.CrossRefGoogle ScholarPubMed
19.Martinot, JL, Allilaire, JF, Mazoyer, BM, Hantouche, E, Huret, JD, Legaut-Demare, F, Deslauriers, AG, Hardy, P, Pappata, S, Baron, JC, Syrota, A. Obsessive-compulsive disorder: a clinical, neuropsychological and positron emission tomography study. Acta psychiat scand 1990; 82: 233-42.CrossRefGoogle ScholarPubMed
20.Zohar, J, Insel, TR, Faith Berman, K, Foa, EB, Hill, JL, Weinberger, DR. Anxiety and cerebral blood flow during behavioral challenge. Dissociation of central from peripheral and subjective measures. Arch gen Psychiat 1989; 46: 505-10.CrossRefGoogle ScholarPubMed
21.Machlin, SR, Harris, GJ, Pearlson, GD, Hoehn-Saric, R, Jeffrey, P, Camargo. Elevated medial-frontal cerebral flood flow in obsessive-compulsive patients: a SPECT study. Am J Psychiat 1991; 148: 1240-2.Google Scholar
22.Hoehn-Saric, R, Pearlson, GD, Harris, GJ, Machlin, SR, Camargo, EE. Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients. Am J Psychiat 1991; 148: 1243-5.Google ScholarPubMed
23.Hollander, E, Schiffman, E, Cohen, B, Rivera-Stein, MA, Rosen, W, Gorman, JM, Fyers, AJ, Papp, L, Liebowitz, MR. Signs of central nervous system dysfunction in obsessive-compulsive disorder. Arch gen Psychiat 1990; 47: 27–32.CrossRefGoogle ScholarPubMed
24.Laplane, D, Levasseur, M, Pillon, B, Dubois, B, Baulas, M, Mazoyer, B, Tran Dinh, S, Sette, G, Danze, F, Baron, JC. Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. Brain 1989; 112: 699–725.CrossRefGoogle ScholarPubMed
25.Rapoport, JL, Wise, SP. Obsessive-compulsive disorder: evidence for basal ganglia dysfunction. Psychopharmacol Bull 1988; 24: 380–4.Google ScholarPubMed